March 5, 2013 - LifeVest Wearable Defibrillator and Advanced Resuscitation Technology to be Showcased at ACC 2013

MEDIA CONTACT:  

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com  

 

ZOLL LIFEVEST WEARABLE DEFIBRILLATOR AND ADVANCED RESUSCITATION TECHNOLOGY TO BE SHOWCASED AT ACC 2013

 

March 5, 2013—CHELMSFORD, MASS.—ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that that it will highlight the LifeVest® Wearable Defibrillator, RescueNet® 12-Lead, and the AutoPulse® Non-invasive Cardiac Support Pump in Booth #N5547 at the 2013 American College of Cardiology Annual Scientific Session and Expo, March 9-11 at the Moscone Center in San Francisco.

The LifeVest will be discussed during a scientific presentation. Peerawut Deeprasertku, MD, Michigan State University, will present “National Experience with Wearable Cardioverter Defibrillator Use in Takotsubo Cardiomyopathy,” Sunday, March 10, 3:45 p.m.–4:30 p.m., Presentation #1235M-31.

A presentation focused on the LifeVest entitled “Sudden Cardiac Death in Post-AMI Patients — Who Is at Risk?” will be presented by David E. Kandzari, MD, Piedmont Heart Institute, Saturday, March 9, 3:45 p.m.–4:45 p.m., in Expo North, #N5141.

The LifeVest Wearable Cardioverter Defibrillator protects patients at risk for sudden cardiac death. It is used to protect a wide range of patients, including recent MI, or following coronary revascularization. Following a PCI procedure, 1 in 5 patients have been shown to be at high risk of early mortality.1 In post-PCI patients with a low EF (≤35%), 3 month mortality is 13%2, and increases significantly in the presence of other risk factors3. The LifeVest gives physicians time to optimize medical therapy and assess a patient’s long-term risk for sudden death.

The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from sudden cardiac arrest (SCA). The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans.

Additional products on display from ZOLL include: 

  • RescueNet 12-Lead is a versatile transmission system that allows health care providers to receive and manage 12-lead ECGs from just about anywhere. It is browser based for maximum flexibility and universal access. RescueNet 12-lead data can be accessed via e-mail, fax, computer, tablet, or handheld simultaneously. The system is safe and effective for hospitals.
  • The AutoPulse is an automated, portable chest compression device. It is the only mechanical CPR system to have shown improved survival in comparative clinical trials4. The AutoPulse more than tripled survival compared to typical CPR during witnessed shockable arrests.

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 25,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.

©2013 ZOLL Medical Corporation. All rights reserved. AutoPulse, LifeVest, RescueNet, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All trademarks are the property of their respective owners.

1Halkin, A et al. Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: CADILLAC Risk Score. JACC 2005;45:1397–1405.
2Zishiri E, et al. Use of the Wearable Cardioverter Defibrillator and Survival After Coronary Artery Revascularization in Patients with Left Ventricular Dysfunction. Circulation 2011; 124:A9816.
3Weintraub et al. Prediction of Long-Term Mortality After Percutaneous Coronary Intervention in Older Adults: Results From the National Cardiovascular Data Registry. Circulation 2012;125:1501–1510.
4Wik L, et al. The impact of CPR duration on survival to discharge between integrated AutoPulse-CPR and manual–CPR during out-of-hospital cardiac arrest of presumed cardiac origin. Resuscitation. 2012;83:e17